Table 2.
Clinical trials of drug combinations
| Target | Disease | Agent | Phase | Clinical Trial Number | Status/ Results |
|---|---|---|---|---|---|
| KRAS-G12C+SOS1 | PDAC | MRTX849+BI1701963 | I | NCT049752356 | Recruiting |
| ERK+SHP2 | PDAC | LY3214996+RMC4630 | I | NCT04916236 | Active |
| ERK+autophagy | Solid tumor | Binimetinib+ hydroxychloroquine | I | NCT04132505 | Recruiting |
| KRAS-G12C+SHP2 | PDAC | MRTX849+TN0155 | I、II | NCT04330664 | Active |
| ERK+BRAF | PDAC | Binimetinib+Encorafenib | II | NCT04390243 | Recruiting |
| MEK+autophagy | PADC | Trametinib+ hydroxychloroquine | I | NCT03825289 | Recruiting |
| CDK4/6+PI3K | PDAC | Palbociclib+Gedatolisib | I | NCT03065062 | Recruiting |
| PI3K+mTOR | Solid tumor | Alpelisib+Everolimus | I | NCT02677933 | Recruiting |